Your browser is no longer supported. Please, upgrade your browser.
QDEL Quidel Corporation monthly Stock Chart
Quidel Corporation
Index- P/E22.06 EPS (ttm)8.52 Insider Own1.50% Shs Outstand42.11M Perf Week-1.57%
Market Cap8.07B Forward P/E4.82 EPS next Y38.99 Insider Trans-4.70% Shs Float37.10M Perf Month-28.73%
Income370.80M PEG3.06 EPS next Q10.07 Inst Own87.30% Short Float6.56% Perf Quarter15.36%
Sales1.00B P/S8.03 EPS this Y-0.50% Inst Trans-2.80% Short Ratio1.81 Perf Half Y7.48%
Book/sh20.17 P/B9.32 EPS next Y105.84% ROA36.20% Target Price289.00 Perf Year172.50%
Cash/sh1.81 P/C104.12 EPS next 5Y7.20% ROE56.50% 52W Range67.06 - 306.72 Perf YTD150.57%
Dividend- P/FCF41.64 EPS past 5Y59.90% ROI15.20% 52W High-38.71% Beta0.53
Dividend %- Quick Ratio2.20 Sales past 5Y23.80% Gross Margin73.90% 52W Low180.35% ATR15.76
Employees1250 Current Ratio2.70 Sales Q/Q276.40% Oper. Margin46.60% RSI (14)40.64 Volatility5.07% 7.30%
OptionableYes Debt/Eq0.01 EPS Q/Q1335.40% Profit Margin36.90% Rel Volume0.40 Prev Close180.76
ShortableYes LT Debt/Eq0.00 EarningsOct 29 AMC Payout0.00% Avg Volume1.35M Price188.00
Recom2.50 SMA20-14.17% SMA50-18.50% SMA2003.05% Volume533,757 Change4.01%
May-12-20Downgrade JP Morgan Neutral → Underweight $120 → $158
Mar-26-20Downgrade Barclays Overweight → Equal Weight $90
Oct-23-18Resumed Raymond James Strong Buy $80
Mar-08-18Upgrade Raymond James Outperform → Strong Buy
Jan-22-18Reiterated Barclays Overweight $50 → $60
Jan-04-18Upgrade CL King Neutral → Buy
Sep-19-17Upgrade Piper Jaffray Neutral → Overweight
Jul-18-17Upgrade William Blair Mkt Perform → Outperform
Jul-18-17Upgrade Canaccord Genuity Hold → Buy $25 → $42
Apr-25-17Reiterated Canaccord Genuity Hold $24 → $24.50
Feb-17-17Initiated CL King Neutral
Dec-16-16Downgrade Piper Jaffray Overweight → Neutral
Jun-13-16Upgrade Raymond James Mkt Perform → Outperform
Feb-18-16Reiterated Barclays Overweight $28 → $22
Feb-09-16Downgrade Canaccord Genuity Buy → Hold $22 → $18
Jan-08-16Reiterated Canaccord Genuity Buy $25 → $22
Dec-14-15Downgrade Raymond James Outperform → Mkt Perform
Sep-02-15Initiated Barclays Overweight $28
Jul-31-13Reiterated Canaccord Genuity Buy $30 → $35
Mar-03-11Downgrade Wedbush Outperform → Neutral $14 → $13
Nov-27-20 12:45PM  
Nov-25-20 11:30AM  
Nov-19-20 01:03PM  
Nov-16-20 09:40AM  
Nov-13-20 10:02AM  
Nov-12-20 07:30AM  
Nov-10-20 06:00PM  
Nov-09-20 03:52PM  
Nov-08-20 03:29AM  
Nov-07-20 06:30AM  
Nov-05-20 01:31PM  
Nov-04-20 03:25PM  
Nov-03-20 04:10PM  
Nov-02-20 08:40AM  
Oct-29-20 07:15PM  
Oct-28-20 11:51AM  
Oct-27-20 10:36AM  
Oct-26-20 05:02PM  
Oct-23-20 11:36AM  
Oct-22-20 05:50PM  
Oct-21-20 08:43AM  
Oct-19-20 04:10PM  
Oct-17-20 07:09AM  
Oct-16-20 08:54AM  
Oct-12-20 09:00AM  
Oct-09-20 01:56PM  
Oct-08-20 08:39AM  
Oct-07-20 09:10PM  
Oct-06-20 12:10PM  
Oct-05-20 09:39AM  
Oct-03-20 08:27AM  
Oct-02-20 07:15PM  
Oct-01-20 02:22PM  
Sep-28-20 06:10PM  
Sep-23-20 05:50PM  
Sep-21-20 03:39PM  
Sep-17-20 07:19AM  
Sep-14-20 11:34PM  
Sep-11-20 12:09PM  
Sep-08-20 03:58PM  
Sep-07-20 05:10AM  
Sep-04-20 11:30AM  
Sep-01-20 02:20PM  
Aug-31-20 12:33PM  
Aug-29-20 09:09AM  
Aug-28-20 10:17AM  
Aug-27-20 05:07PM  
Aug-26-20 03:03PM  
Aug-25-20 11:00AM  
Aug-23-20 09:00AM  
Aug-22-20 07:12AM  
Aug-20-20 02:30PM  
Aug-19-20 09:30PM  
Aug-18-20 05:48AM  
Aug-14-20 07:16AM  
Aug-13-20 12:48PM  
Aug-12-20 06:00PM  
Aug-10-20 06:38PM  
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
POLAN MARY LAKE PH DDirectorNov 06Sale284.173,000852,50535,329Nov 06 07:19 PM
SLACIK CHARLES PDirectorNov 05Option Exercise20.824,00983,46715,224Nov 06 07:16 PM
SLACIK CHARLES PDirectorNov 05Sale282.464,0091,132,38811,215Nov 06 07:16 PM
POLAN MARY LAKE PH DDirectorOct 23Option Exercise21.6327,188588,14238,329Oct 27 07:37 PM
POLAN MARY LAKE PH DDirectorOct 12Sale275.8311,7433,239,01511,141Oct 14 07:26 PM
Strobeck MatthewDirectorSep 03Buy155.6340062,25438,145Sep 04 07:09 PM
Strobeck MatthewDirectorSep 02Buy166.657,3001,216,51137,745Sep 04 07:09 PM
BRYANT DOUGLAS CPresident & CEOAug 31Buy174.995,000874,965455,823Sep 01 06:05 PM
Abney Michael Donald Jr.SVP - DistributionAug 20Option Exercise34.142,58288,1439,216Aug 24 12:03 PM
Abney Michael Donald Jr.SVP - DistributionAug 20Sale250.002,582645,5006,634Aug 24 12:03 PM
Abney Michael Donald Jr.SVP - DistributionAug 19Option Exercise35.875,610201,21512,244Aug 24 12:03 PM
Abney Michael Donald Jr.SVP - DistributionAug 19Sale250.005,6101,402,5006,634Aug 24 12:03 PM
BRYANT DOUGLAS CPresident & CEOAug 11Buy234.125,0001,170,600450,823Aug 11 08:38 PM
BUECHLER KENNETH FDirectorAug 03Option Exercise14.437,800112,55467,624Aug 05 08:26 PM
STEWARD RANDALL JChief Financial OfficerAug 03Option Exercise18.4621,166390,65724,014Aug 05 08:33 PM
Michael Edward L.DirectorAug 03Buy288.123,5001,008,4046,434Aug 05 08:32 PM
STEWARD RANDALL JChief Financial OfficerAug 03Sale286.3121,1666,060,1262,848Aug 05 08:33 PM
Kroll WernerSVP, R&DAug 03Sale287.482,072595,6504,599Aug 05 08:28 PM
BUECHLER KENNETH FDirectorAug 03Sale289.227,8002,255,94659,824Aug 05 08:26 PM
BRYANT DOUGLAS CPresident & CEOJun 11Buy160.335,000801,670445,823Jun 12 05:53 PM
Kroll WernerSVP, R&DMay 27Option Exercise0.004,37608,975May 27 07:54 PM
Kroll WernerSVP, R&DMay 22Option Exercise20.4668,1521,394,42272,751May 27 07:54 PM
Kroll WernerSVP, R&DMay 22Sale174.4468,15211,888,1494,599May 27 07:54 PM
Bujarski Robert JosephSVP, NA Comm Ops & Gen CounselMay 20Sale189.4120,0003,788,28213,383May 22 07:59 PM
Abney Michael Donald Jr.SVP - DistributionMay 18Option Exercise17.9515,970286,67515,432May 20 08:02 PM
BORKAR RATAN SSVP, Intl Comm OperationsMay 18Option Exercise31.8816,332520,69927,171May 20 08:07 PM
STEWARD RANDALL JChief Financial OfficerMay 18Sale185.3520,0003,707,0402,848May 20 08:11 PM
BORKAR RATAN SSVP, Intl Comm OperationsMay 18Sale192.8228,3125,459,113524May 20 08:07 PM
Abney Michael Donald Jr.SVP - DistributionMay 18Sale198.4615,9703,169,3876,634May 20 08:02 PM
BUECHLER KENNETH FDirectorMay 15Option Exercise0.001,842059,824May 18 08:06 PM
SLACIK CHARLES PDirectorMay 15Option Exercise0.00549011,352May 18 08:16 PM
SLACIK CHARLES PDirectorMay 14Option Exercise0.002,100010,803May 18 08:16 PM
SCHULER JACK WDirectorMay 14Option Exercise0.002,10003,103,249May 18 08:14 PM
POLAN MARY LAKE PH DDirectorMay 14Option Exercise0.002,100022,884May 18 08:12 PM
ORDONEZ KATHYDirectorMay 14Option Exercise0.001,85601,856May 18 08:10 PM
Michael Edward L.DirectorMay 14Option Exercise0.002,10002,934May 18 08:08 PM
BUECHLER KENNETH FDirectorMay 14Option Exercise0.002,100057,982May 18 08:06 PM
WIDDER KENNETH JDirectorMay 14Option Exercise0.002,100014,416May 18 08:21 PM
Strobeck MatthewDirectorMay 14Option Exercise0.002,10007,399May 18 08:19 PM
POLAN MARY LAKE PH DDirectorMay 11Sale204.276,7001,368,63020,784May 12 08:01 PM
BUECHLER KENNETH FDirectorMay 11Sale200.005,0001,000,00055,882May 13 08:01 PM
BUECHLER KENNETH FDirectorMay 05Option Exercise13.2510,449138,44960,882May 07 08:05 PM
Russell Edward KeithSVP, Business DevelopmentFeb 26Option Exercise15.4012,601194,05529,791Feb 28 08:03 PM
Russell Edward KeithSVP, Business DevelopmentFeb 26Sale79.5812,6011,002,79617,190Feb 28 08:03 PM
POLAN MARY LAKE PH DDirectorJan 07Option Exercise21.079,041190,49428,584Jan 09 08:23 PM
BORKAR RATAN SSVP, Intl Comm OperationsDec 06Option Exercise15.6711,122174,22620,426Dec 09 07:59 PM
BORKAR RATAN SSVP, Intl Comm OperationsDec 06Sale70.0011,122778,5409,304Dec 09 07:59 PM
BORKAR RATAN SSVP, Intl Comm OperationsDec 05Option Exercise23.414,700110,02714,004Dec 09 07:59 PM
BORKAR RATAN SSVP, Intl Comm OperationsDec 05Sale70.004,700329,0009,304Dec 09 07:59 PM
Kroll WernerSVP, R&DDec 03Option Exercise22.856,620151,26723,389Dec 05 09:35 PM
Kroll WernerSVP, R&DDec 03Sale68.0222,9511,561,0783,795Dec 05 09:35 PM